Topics

Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity.

08:00 EDT 16th April 2019 | BioPortfolio

Summary of "Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity."

To evaluate the efficacy of a single injection of 0.3 mg of intravitreal ranibizumab for the treatment of retinopathy of prematurity.

Affiliation

Journal Details

This article was published in the following journal.

Name: Medical principles and practice : international journal of the Kuwait University, Health Science Centre
ISSN: 1423-0151
Pages:

Links

DeepDyve research library

PubMed Articles [18309 Associated PubMed Articles listed on BioPortfolio]

Iatrogenic Crystalline Lens Injury in Pediatric Eyes Following Intravitreal Injection for Retinopathy of Prematurity.

To report the occurrence of lens injury during intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in infants with retinopathy of prematurity (ROP).

Short-term intraocular pressure changes after intravitreal injection of bevacizumab for retinopathy of prematurity.

To evaluate the short-term changes in intraocular pressure (IOP) after intravitreal injection of bevacizumab (IVB) in premature infants with retinopathy of prematurity (ROP).

Neurodevelopmental Outcomes Following Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: a prospective, case-control study.

To evaluate the neurodevelopmental and ocular developmental outcomes in premature children who have undergone intravitreal bevacizumab injection (IVB) for treatment of type 1 retinopathy of prematurit...

The Impact of Prefilled Syringes on Endophthalmitis following Intravitreal Injection of Ranibizumab.

To compare the rates of infectious endophthalmitis following intravitreal injection of ranibizumab using prefilled syringes vs. conventional preparation.

Extended (≥q12 Weeks) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular AMD: Post Hoc Analysis of VIEW Trials.

To evaluate outcomes and disease characteristics in eyes with neovascular age-related macular degeneration that received intravitreal aflibercept injection (IAI) and ranibizumab ≥q12 or

Clinical Trials [5421 Associated Clinical Trials listed on BioPortfolio]

Rainbow Extension Study

The purpose of this study is to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of ...

Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)

To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic r...

Use of Pan-Vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

The purpose of this study is to provide access to intravitreal injection of Avastin in high-risk infants who do not otherwise qualify for study NCT00702819, an investigational multi-site s...

Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness...

Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panret...

Medical and Biotech [MESH] Definitions

A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)

A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.

Total or subtotal destruction of the pituitary gland by chemical injection. It is usually achieved by injection of ethyl alcohol via trans-sphenoidal cannulation under stereotaxic control. It is usually performed for the treatment of intractable pain.

The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.

Adverse reactions that occur initially at the site of injection or infusion. Milder type is confined to a local allergic flare reaction. A more severe reaction is caused by extravasation of VESICANTS from the blood vessel at the site of injection and can cause damage to the surrounding tissue. In tumor flare reaction symptoms involve well beyond the injection site such as an increase in the tumor size and tumor markers levels, bone pain, and HYPERCALCEMIA.

Quick Search


DeepDyve research library

Searches Linking to this Article